{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atrasentan", "query": { "intervention": "Atrasentan" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Atrasentan&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T03:24:52.531Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00038662", "title": "Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Atrasentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "MALE", "summary": "19 Years and older · Male only" }, "enrollment_count": 200, "start_date": "2002-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-08-15", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 24, "location_summary": "Homewood, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038662" }, { "nct_id": "NCT00134056", "title": "S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Cancer", "Prostate Cancer" ], "interventions": [ { "name": "atrasentan hydrochloride", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1038, "start_date": "2006-08", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 554, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134056" }, { "nct_id": "NCT00653328", "title": "Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "atrasentan hydrochloride", "type": "DRUG" }, { "name": "doxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2003-05", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2012-05-23", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 6, "location_summary": "Macon, Georgia • Louisville, Kentucky • Germantown, Tennessee + 2 more", "locations": [ { "city": "Macon", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00653328" }, { "nct_id": "NCT00920764", "title": "A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease", "Diabetic Nephropathy" ], "interventions": [ { "name": "Placebo for Atrasentan 0.2 mg/mL solution", "type": "DRUG" }, { "name": "0.25 mg Atrasentan QD", "type": "DRUG" }, { "name": "0.75 mg Atrasentan QD", "type": "DRUG" }, { "name": "1.75 mg Atrasentan QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2009-06", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 24, "location_summary": "Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Azusa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00920764" }, { "nct_id": "NCT07498335", "title": "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Berger Disease", "Bergers Disease", "IgA Nephropathy", "Immunoglobulin A Nephropathy", "Primary IgAN", "Nephritis IgA Type, Nephropathy IgA Type" ], "interventions": [ { "name": "Drug: Atrasentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 28, "start_date": "2026-08-26", "completion_date": "2032-12-13", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 4, "location_summary": "Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Neptune City", "state": "New Jersey" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07498335" }, { "nct_id": "NCT04573920", "title": "Atrasentan in Patients With Proteinuric Glomerular Diseases", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgA Nephropathy", "Focal Segmental Glomerulosclerosis", "Alport Syndrome", "Diabetic Kidney Disease", "Diabetic Nephropathy Type 2", "Immunoglobulin A Nephropathy" ], "interventions": [ { "name": "Atrasentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2021-03-15", "completion_date": "2026-10-27", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 14, "location_summary": "Glendale, California • Los Angeles, California • San Dimas, California + 11 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Dimas", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04573920" }, { "nct_id": "NCT01356849", "title": "Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease", "Diabetic Nephropathy" ], "interventions": [ { "name": "Atrasentan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2011-04", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-08-28", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 59, "location_summary": "Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more", "locations": [ { "city": "Pell City", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Azusa", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356849" }, { "nct_id": "NCT00271492", "title": "Correlation of Endothelial Function and Early Coronary Artery Disease in Humans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endothelial Dysfunction" ], "interventions": [ { "name": "atrasentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 200, "start_date": "2001-07", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2010-04-30", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00271492" }, { "nct_id": "NCT06952426", "title": "A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immunoglobulin A Nephropathy" ], "interventions": [ { "name": "No intervention", "type": "OTHER" }, { "name": "Other treatment", "type": "OTHER" }, { "name": "Iptacopan", "type": "OTHER" }, { "name": "Atrasentan", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-03-04", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952426" }, { "nct_id": "NCT00017264", "title": "Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "atrasentan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-01-13", "last_synced_at": "2026-09-04T03:24:52.531Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017264" } ] }